Early bronchodilatory response to the first dose of indacaterol/glycopyrronium as an additional individual predictor of their effectiveness in the treatment of chronic obstructive pulmonary disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The effectiveness of the early bronchodilatory response of the first dose of a fixed double combination of long-acting bronchodilators of various classes indacaterol/glycopyrronium and long-acting anticholinergics glycopyrronium and Tiotropium in patients suffering from stable chronic obstructive pulmonary disease is compared. It was found that in all patients included in the study and suffering from chronic obstructive pulmonary disease, changes in functional respiratory indicators were accompanied by positive and comparable dynamics of clinical signs: a decrease in the severity of shortness of breath, the impact of the disease on the quality of life and increased tolerance to physical activity. It was found that the combination of indacaterol/glycopyrronium provides rapid, pronounced and prolonged bronchodilation in patients suffering from chronic obstructive pulmonary disease compared to the separate use of glycopyrronium and Tiotropium. Consistent use of glycopyrronium and salbutamol leads to maximum bronchodilation, which makes it advisable to separate the use of prolonged bronchodilators when initiating therapy for chronic obstructive pulmonary disease. Therefore, there is a clinical feasibility of taking not only fixed combinations of bronchodilators of different classes, but also their consistent use. The results of an early bronchodilatory response to the first dose of indacaterol/glycopyrronium can be used as an additional individual predictor of their effectiveness in the treatment of chronic obstructive pulmonary disease.

About the authors

N. V. Sharova

Military medical academy of S.M. Kirov

Author for correspondence.
Email: vmeda-nio@mil.ru
Russian Federation, Saint Petersburg

S. L. Grishaev

Military medical academy of S.M. Kirov

Email: vmeda-nio@mil.ru
Russian Federation, Saint Petersburg

D. V. Cherkashin

Military medical academy of S.M. Kirov

Email: vmeda-nio@mil.ru
Russian Federation, Saint Petersburg

S. V. Efimov

Military medical academy of S.M. Kirov

Email: vmeda-nio@mil.ru
Russian Federation, Saint Petersburg

M. A. Kharitonov

Military medical academy of S.M. Kirov

Email: vmeda-nio@mil.ru
Russian Federation, Saint Petersburg

A. I. Zakharova

Military medical academy of S.M. Kirov

Email: vmeda-nio@mil.ru
Russian Federation, Saint Petersburg

I. M. Zakharova

Military medical academy of S.M. Kirov

Email: vmeda-nio@mil.ru
Russian Federation, Saint Petersburg

References

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Increase in FEV1 (a) and the number of patients with OBO (b) in pharmacological tests with various bronchodilators: Sat - 15 minutes after 400 μg of salbutamol; Ber - 30 minutes after berodual; TIO - 60 minutes after 18 μg of tiotropium; TIO + Sat - 90 minutes after 18 tiotropium and 400 μg salbutamol; GLI - 60 minutes after 50 μg of glycopyrronium; GLI + Sat - 90 minutes after 50 μg of glycopyrronium and 400 μg of salbutamolo; IND / GLI 30 - 30 minutes after the combination IND / GLI 110/50 μg; IND / GLI 60 - 60 minutes after the combination IND / GLI 110/50 μg

Download (112KB)
3. Fig. 2. Types of bronchodilatory response: a - the response to GLI is highlighted in blue; c - the answer to the IND / GLI is highlighted in red

Download (220KB)

Copyright (c) 2020 Sharova N.V., Grishaev S.L., Cherkashin D.V., Efimov S.V., Kharitonov M.A., Zakharova A.I., Zakharova I.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies